Navigation Links
Divergence Receives $1.2 Million in Grants, Including NSF Grant to Fund Continuing Nematode Research in Corn
Date:4/29/2009

Company's work could help farmers protect against billions in pest losses annually

St. Louis, MO (PRWEB) April 29, 2009 -- In the past year, St. Louis biotech firm Divergence, Inc., has received more than $1.2 million in research grants, including a $500,000 grant just awarded from the National Science Foundation (NSF) to further the company's work on biotech traits for lesion nematode control in crops such as corn. The Phase II grant, "Control of Lesion Nematodes by RNA Interference," is part of NSF's Small Business Innovation Research (SBIR) program.

Nematodes are the largest unsolved pest problem in agriculture, limiting the yield of crops worldwide and causing billions of dollars in crop damage annually. Lesion nematodes are prevalent in the Corn Belt and appear to be increasing with changing agronomic practices. Divergence, a world leader in developing products for control of parasites in agriculture and medicine, has discovered nematicidal chemistry working through a novel mode of action and is also working on biotechnology-derived crops with built-in pest resistance.

The company's Phase I research demonstrated that RNA interference (RNAi) can substantially reduce lesion nematode reproduction resulting in a larger, healthier root system for a plant. The Phase II grant will allow Divergence to expand greenhouse testing in crops including corn. RNAi is a fundamental mechanism of gene regulation triggered by double-stranded RNA. Divergence was an early industrial adopter of RNAi, working with the research platform since the company's inception in 1999. Dr. Craig Mello, a member of Divergence's Scientific Advisory Board since 2000, was the co-recipient of the 2006 Nobel Prize in Physiology or Medicine for the discovery of RNAi.

"Our project's findings could lead to corn yield increases in the field as well as improvement in the ability of corn to tolerate drought conditions," said Dr. James McCarter, Divergence founder, president and chief scientific officer. "These pests are unseen to the naked eye and cause far more damage than is generally recognized. We're very pleased to have this funding support which will allow us to accelerate the project."

Other recent SBIR grants to Divergence include support from the National Institutes of Health (NIH) and U.S. Department of Agriculture (USDA):

  • Two $100,000 NIH Phase I Grants for anthelmintic and antifungal drug discovery and a $10,000 NIH Manufacturing Assistance Program Grant
  • One USDA $350,000 Phase II Grant and two USDA $80,000 Phase I Grants for control of root knot nematodes and fungal infections in plants.

Additionally, the National Corn Growers Association (NCGA) has provided research collaboration funding to the company for each of the past seven years to help support the association's research efforts toward a biotechnology solution to nematodes in corn.

"NCGA recognizes the potential value this research could provide our farmers in terms of new, safe approaches to control nematodes that plague corn and other crops," said Dr. Richard Glass, NCGA vice president of research and business development. "We are always seeking solutions that allow corn growers to produce a more abundant crop more profitably."

The company, which recently announced that it secured $11.8 million in Series C equity financing, is also working on solutions for parasite control in animals and humans.

About Divergence:
Divergence, Inc., a world leader in the application of genomics and informatics to agriculture and infectious disease, discovers and develops products for the safe and effective control of parasites. The company's initial focus is on parasitic nematodes, devastating unseen pests that cause billions of dollars in crop loss annually and widespread disease in humans and animals. For more information visit Divergence's Web site at www.divergence.com.

# # #

Read the full story at http://www.prweb.com/releases/2009/04/prweb2362954.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Divergence Raises $11.8 Million in Series C Financing
2. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
3. China Biologic Products Receives $5.3 Million Order from Largest Biopharmaceutical Distributor in India
4. China Medical Technologies Receives SFDA Approval for Its Bladder Cancer FISH Probe
5. Mach One BioPharm Process Operating Group Receives Contract From American Beef Processors
6. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
7. Sunesis Pharmaceuticals Receives NASDAQ Notification
8. XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
9. Cambrex Receives Notice Regarding NYSE Listing
10. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
11. Vertebral Technologies Receives Award for InterFuse(R) Interbody Fusion System
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Divergence Receives $1.2 Million in Grants, Including NSF Grant to Fund Continuing Nematode Research in Corn
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
Breaking Biology Technology:
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
Breaking Biology News(10 mins):